Prostate Cancer
Macrogenics Inc. focuses on clinical research in metastatic castration-resistant prostate cancer, with studies centered on treatment options for advanced disease that no longer responds to standard hormone suppression.
- Metastatic castration-resistant prostate cancer
- Advanced prostate malignancy
The sponsor’s trial portfolio in this area examines disease control and progression outcomes in patients with difficult-to-treat prostate cancer.
Targeted Antibody-Based Therapy
Its research includes vobramitamab duocarmazine, reflecting interest in antibody-based treatment strategies designed for oncology applications in advanced prostate cancer.
- Vobramitamab duocarmazine
- Antibody-drug conjugate therapy
This area highlights therapeutic development aimed at improving disease management in metastatic settings.
Immuno-Oncology
Macrogenics also studies lorigerlimab in combination with docetaxel, indicating active involvement in immuno-oncology approaches for resistant prostate cancer.
- Lorigerlimab
- Combination therapy
- Docetaxel
The therapeutic focus extends to combination regimens used in patients with advanced, treatment-refractory disease.
Metastatic Disease Management
The sponsor’s clinical activity is directed toward metastatic disease assessment, with particular attention to radiographic measures of progression in advanced genitourinary oncology.
- Radiographic progression assessment
- Genitourinary oncology
- Disease progression control
Research sites across multiple countries support studies focused on treatment response in metastatic castration-resistant prostate cancer.
